Cargando…
Cinacalcet Treatment of Primary Hyperparathyroidism
Although parathyroidectomy remains the only curative approach to most primary hyperparathyroidism cases, medical treatment with cinacalcet HCl has been proven to be a reasonable alternative for several patient subgroups. Cinacalcet almost always controls hypercalcemia and hypophosphatemia sufficient...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065008/ https://www.ncbi.nlm.nih.gov/pubmed/21461394 http://dx.doi.org/10.1155/2011/415719 |
_version_ | 1782200940146720768 |
---|---|
author | Rothe, H. M. Liangos, O. Biggar, P. Petermann, A. Ketteler, M. |
author_facet | Rothe, H. M. Liangos, O. Biggar, P. Petermann, A. Ketteler, M. |
author_sort | Rothe, H. M. |
collection | PubMed |
description | Although parathyroidectomy remains the only curative approach to most primary hyperparathyroidism cases, medical treatment with cinacalcet HCl has been proven to be a reasonable alternative for several patient subgroups. Cinacalcet almost always controls hypercalcemia and hypophosphatemia sufficiently. PTH levels are lowered, and cognitive parameters improve. While an increase in bone mineral density DEXA scan scores was not demonstrated in cinacalcet trials, the same applies to more than half of patients after parathyroidectomy. Medical therapy should be first choice in patients with hyperplasia in all glands rather than an isolated adenoma (10–15%), patients with persisting HPT following unsuccessful surgery or inoperable cases due to comorbidities, and patients detected in lab screens for hypercalcemia before developing symptoms who should be treated early but are usually reluctant to undergo surgery. Nephrolithiasis was not found to occur more frequently in cinacalcet trial groups, but urine calcium excretion as one major risk factor of this complication of primary HPT may increase on cinacalcet. Patients carrying the rs1042636 polymorphism of the calcium-sensing receptor gene respond more sensitively to cinacalcet and have a higher risk of calcium stone formation. Cinacalcet is usually administered twice daily but three or four doses per day should be discussed to mimic the beneficial pulsatile PTH-pattern. |
format | Text |
id | pubmed-3065008 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-30650082011-03-31 Cinacalcet Treatment of Primary Hyperparathyroidism Rothe, H. M. Liangos, O. Biggar, P. Petermann, A. Ketteler, M. Int J Endocrinol Review Article Although parathyroidectomy remains the only curative approach to most primary hyperparathyroidism cases, medical treatment with cinacalcet HCl has been proven to be a reasonable alternative for several patient subgroups. Cinacalcet almost always controls hypercalcemia and hypophosphatemia sufficiently. PTH levels are lowered, and cognitive parameters improve. While an increase in bone mineral density DEXA scan scores was not demonstrated in cinacalcet trials, the same applies to more than half of patients after parathyroidectomy. Medical therapy should be first choice in patients with hyperplasia in all glands rather than an isolated adenoma (10–15%), patients with persisting HPT following unsuccessful surgery or inoperable cases due to comorbidities, and patients detected in lab screens for hypercalcemia before developing symptoms who should be treated early but are usually reluctant to undergo surgery. Nephrolithiasis was not found to occur more frequently in cinacalcet trial groups, but urine calcium excretion as one major risk factor of this complication of primary HPT may increase on cinacalcet. Patients carrying the rs1042636 polymorphism of the calcium-sensing receptor gene respond more sensitively to cinacalcet and have a higher risk of calcium stone formation. Cinacalcet is usually administered twice daily but three or four doses per day should be discussed to mimic the beneficial pulsatile PTH-pattern. Hindawi Publishing Corporation 2011 2011-03-06 /pmc/articles/PMC3065008/ /pubmed/21461394 http://dx.doi.org/10.1155/2011/415719 Text en Copyright © 2011 H. M. Rothe et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Rothe, H. M. Liangos, O. Biggar, P. Petermann, A. Ketteler, M. Cinacalcet Treatment of Primary Hyperparathyroidism |
title | Cinacalcet Treatment of Primary Hyperparathyroidism |
title_full | Cinacalcet Treatment of Primary Hyperparathyroidism |
title_fullStr | Cinacalcet Treatment of Primary Hyperparathyroidism |
title_full_unstemmed | Cinacalcet Treatment of Primary Hyperparathyroidism |
title_short | Cinacalcet Treatment of Primary Hyperparathyroidism |
title_sort | cinacalcet treatment of primary hyperparathyroidism |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065008/ https://www.ncbi.nlm.nih.gov/pubmed/21461394 http://dx.doi.org/10.1155/2011/415719 |
work_keys_str_mv | AT rothehm cinacalcettreatmentofprimaryhyperparathyroidism AT liangoso cinacalcettreatmentofprimaryhyperparathyroidism AT biggarp cinacalcettreatmentofprimaryhyperparathyroidism AT petermanna cinacalcettreatmentofprimaryhyperparathyroidism AT kettelerm cinacalcettreatmentofprimaryhyperparathyroidism |